LLY
Eli Lilly and Company
NYSE: LLY · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$883.96
-3.67% today
Updated 2026-04-24
Market cap
$824.74B
P/E ratio
40.17
P/S ratio
12.65x
EPS (TTM)
$22.94
Dividend yield
0.66%
52W range
$620 – $1,132
Volume
2.9M
WallStSmart proprietary scores
78
out of 100
Grade: B+
Buy
Investment rating
10.0
Growth
A+6.5
Quality
B10.0
Profitability
A+5.0
Valuation
C+6/9
Piotroski F-Score
Moderate
2.1
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$1,209.86
+36.87%
12-Month target
$686.31
-22.36%
Intrinsic (DCF)
—
Margin of safety
—
6 Strong Buy18 Buy6 Hold1 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Profit margin 31.70% — above average
+ ROE 101.20% — strong efficiency
+ Free cash flow $677.90M — positive
+ Revenue growth 42.60% QoQ
Risks
- P/E 40.17x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $28.54B | $34.12B | $45.04B | $65.18B | $65.18B | $82.9B |
| Net income | $6.24B | $5.24B | $10.59B | $20.64B | $6.64B | — |
| EPS | — | — | — | — | $22.94 | $34.96 |
| Free cash flow | $4.60B | $-3.15B | $414.30M | $8.97B | $677.90M | — |
| Profit margin | 21.88% | 15.36% | 23.51% | 31.66% | 31.70% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-16 | SULZBERGER, GABRIELLE | Buy | 5 | $989.12 |
| 2026-03-16 | LUCIANO, JUAN R | Buy | 16 | $989.12 |
| 2026-03-16 | FYRWALD, J ERIK | Buy | 10 | $989.12 |
Peer comparison
Smart narrative
Eli Lilly and Company trades at $883.96. representing a P/E of 40.17x trailing earnings. Our Smart Value Score of 78/100 indicates the stock is good. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 2.06, it sits in the grey zone. TTM revenue stands at $65.18B. with profit margins at 31.70%.
Frequently asked questions
What is Eli Lilly and Company's stock price?
Eli Lilly and Company (LLY) trades at $883.96.
Is Eli Lilly and Company overvalued?
Smart Value Score 78/100 (Grade B+, Buy).
What is the price target of Eli Lilly and Company (LLY)?
The analyst target price is $1,209.86, representing +36.9% upside from the current price of $883.96.
What is the future stock price of LLY by 2030?
Our research-backed model estimates Eli Lilly and Company could reach $903.02 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Eli Lilly and Company's revenue?
TTM revenue is $65.18B.
Piotroski F-Score?
6/9 — moderate financial health.
Altman Z-Score?
2.06 — grey zone.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio12.65x
ROE101.20%
Beta0.50
50D MA$965.76
200D MA$907.42
Shares out0.89B
Float0.89B
Short ratio—
Avg volume2.9M
Performance
1 week-4.65%
1 month+0.65%
3 months-16.81%
YTD-17.61%
1 year+0.66%
3 years+131.50%
5 years—